Mayne Pharma Group Ltd (ASX: MYX) has agreed to a takeover bid from Gedeon Richter Plc, with the offer priced at almost double what the company's shares were changing hands for before the deal was announced.
The drug company's shares closed at $3.21 on Monday, 17 November, and the takeover bid is priced at $6.40.
Mayne Pharma shares shot up to $5.71 in early trade on Tuesday, leaving a decent premium of 12.1% to be made if investors buy in and the deal does eventually go through.

Image source: Getty Images
Board and large shareholders back the deal
The deal is being unanimously recommended by the Mayne board. Meanwhile the company's three largest shareholders, Funicular Funds with 9.82%, Bruce Mathieson with 6.46% and Trium Capital with 5.85%, have all indicated they will sell their shares into the deal.
Richter is a specialty pharmaceutical company founded in Hungary 125 years ago, with operations in around 50 countries globally.
The deal is fully funded, Mayne said, and will require approval from Mayne shareholders.
Mayne Chair Bruce Robinson said the deal fulfilled the board's purpose to maximise value for shareholders.
He added:
The Board has carefully considered the proposal from Richter and has unanimously concluded that it is in the best interests of Mayne Pharma shareholders, in the absence of a Superior Proposal and subject to the Independent Expert's conclusion. The Scheme Consideration of $6.40 per share in cash provides shareholders with the opportunity to realise value at a significant premium to recent trading prices and recognises the strength of Mayne Pharma's Women's Health and Dermatology/DistributeRx franchises in the United States.
The deal will be subject to Foreign Investment Review Board approval and is subject to a positive recommendation from an independent expert.
Cosette deal in the rear view mirror
Mayne was the subject of a $7.40 per share takeover bid by US company Cosette, which later tried to back out of the transaction citing a deterioration in Mayne's financial performance.
Mayne took Cosette to court and won a judgment and then a later appeal by Cosette, with the court ruling that, as Mayne said in a statement on 14 October, "no Mayne Material Adverse Change had occurred and that Mayne Pharma did not engage in misleading and deceptive conduct regarding its FY25 EBITDA financial performance''.
Mr Robinson said at the time that Mayne would, "continue to pursue its claims against Cosette, Cosette Pharmaceuticals Holdings, Inc, and its controllers, Mr David Burghstahler and Avista Capital for damages on behalf of itself and Mayne Pharma shareholders''.
The new deal values Mayne's equity at about $604 million.